CrdCrew
Professional Crew Of Carders
Search titles only
By:
Menu
CrdCrew
Home
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search titles only
By:
Latest activity
Register
Contact Admin :
[email protected]
for Purchasing Advertisement or Other Matters
White Rabbit CC-shop! Usa and all world CC (Automated market)
[ TXN ] :: [ BIGGEST SHOP - HIGH VALID & DAILY FRESH UPDATE - BEST OFFER FOR SELLER]
Revolutionary Antidetect Che Browser for Multi-Accounting
VCLUB AUTOMATED CC|DUMPS FRESH DAILY UPDATE / VCLUB Автоматизированный СC|DUMPS Магазин
Home
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
101 dumps
Recent contents
View information
Top users
Description
Intepirdine (INN; developmental codes SB-742457, RVT-101) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects. It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials. GSK chose not to continue development and sold the rights to Axovant Sciences for $5 million in December 2014.
Results of a phase III clinical trial for the treatment of Alzheimer's disease were reported in September 2017. The trial showed no improvement over control group and Axovant lost 70% of its value upon the announcement of the trial results.
Intepirdine also entered clinical trials for dementia with Lewy bodies, also with negative results. Consequently, Axovant announced in 2018 that it has discontinued development of this drug.
View More On Wikipedia.org
Home
Menu
Log in
Register
Forums
What's new
Log in
Register
Search
Top